Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers

【24h】

Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers

机译：获得的抗癫痫抗性的差异机制与Palbociclib揭示了CDK4 / 6治疗抗性乳腺癌的新疗效策略

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal 》 |2020年第2020期| 共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：获得的抗癫痫抗性的差异机制与Palbociclib揭示了CDK4 / 6治疗抗性乳腺癌的新疗效策略
2. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer ( NSCLC ) [J] . Qiong Qin, Xiaoqing Li, Xingmei Liang, Thoracic cancer. . 2020 ,第9期

机译：CDK4 / 6抑制剂Palbociclib克服了非小细胞肺癌（NSCLC）的第三代EGFR抑制剂Osimertinib的获得性
3. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer (vol 77, pg 2488, 2017) [J] . Jansen Valerie M., Bhola Neil E., Bauer Joshua A., Cancer research: The official organ of the American Association for Cancer Research, Inc . 2019 ,第4期

机译：Kinome-宽的RNA干扰筛网显示出PDK1在ER阳性乳腺癌中获得CDK4 / 6抑制的抗性的作用（Vol 77，PG 2488,2017）
4. Quantitative Pathway Analysis of Basal Breast Cancer Cell Line Proteomes Reveals Signaling Features, Potential Therapeutic Targets [C] . Atim A. Enyenihi, Therese Hemstrom, Roman A. Zubarev American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：基础乳腺癌细胞系蛋白质组的定量途径分析显示信号传导特征，潜在的治疗目标
5. The Role of Darpp-32 and t-Darpp in Breast Cancer Tumorigenesis and the Development of Acquired Drug Resistance. [D] . Christenson, Jessica Lynn. 2014

机译：Darpp-32和t-Darpp在乳腺癌肿瘤发生和获得性耐药发展中的作用。
6. Glucose Metabolic Reprogramming of ER+ Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib [O] . Nicla Lorito, Marina Bacci, Alfredo Smiriglia, 2020

机译：对CDK4 / 6抑制剂Palbociclib产生抗性的ER +乳腺癌的葡萄糖代谢重编程
7. New Studies Reveal Potential Mechanisms of Resistance to CDK4 /6 Inhibitors in HR +/ HER2 – Breast Cancer [O] . 2021

机译：新研究揭示了HR + / HER2 - 乳腺癌中CDK4 / 6抑制剂的潜在机制
8. Chemical Strategy to Translate Genetic/Epigenetic Mechanisms to Breast Cancer Therapeutics. [R] . Fu, X. 2014

机译：将遗传/表观遗传机制转化为乳腺癌治疗的化学策略。

Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers

著录项

相似文献

相关主题

期刊订阅